{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:31:01Z","timestamp":1772757061574,"version":"3.50.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,7,11]],"date-time":"2008-07-11T00:00:00Z","timestamp":1215734400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosc"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1007\/s00406-008-0812-0","type":"journal-article","created":{"date-parts":[[2008,7,11]],"date-time":"2008-07-11T19:14:36Z","timestamp":1215803676000},"page":"257-270","source":"Crossref","is-referenced-by-count":31,"title":["Do effectiveness (\u201creal world\u201d) studies on antipsychotics tell us the real truth?"],"prefix":"10.1007","volume":"258","author":[{"given":"Hans-J\u00fcrgen","family":"M\u00f6ller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,7,11]]},"reference":[{"key":"812_CR1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00406-004-0555-5","volume":"255","author":"D Adam","year":"2005","unstructured":"Adam D, Kasper S, M\u00f6ller HJ, Singer EA (2005) Placebo-controlled trials in major depression are necessary and ethically justifiable: how to improve the communication between researchers and ethical committees. Eur Arch Psychiatry Clin Neurosci 255:258\u2013260","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"812_CR2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/070674370404900504","volume":"49","author":"AG Awad","year":"2004","unstructured":"Awad AG, Voruganti LN (2004) New antipsychotics, compliance, quality of life, and subjective tolerability\u2014are patients better off? Can J Psychiatry 49:297\u2013302","journal-title":"Can J Psychiatry"},{"key":"812_CR3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s00406-003-0400-2","volume":"253","author":"D Baldwin","year":"2003","unstructured":"Baldwin D, Broich K, Fritze J, Kasper S, Westenberg H, M\u00f6ller HJ (2003) Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci 253:22\u201328","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"812_CR4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S1461145703004048","volume":"7","author":"Y Barak","year":"2004","unstructured":"Barak Y, Shamir E, Mirecki I, Weizman R, Aizenberg D (2004) Switching elderly chronic psychotic patients to olanzapine. Int J Neuropsychopharmacol 7:165\u2013169","journal-title":"Int J Neuropsychopharmacol"},{"key":"812_CR5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1017\/S1461145705005924","volume":"9","author":"S Bender","year":"2006","unstructured":"Bender S, Dittmann-Balcar A, Schall U, Wolstein J, Klimke A, Riedel M, Vorbach EU, Kuhn KU, Lambert M, Dittmann RW et al (2006) Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. Int J Neuropsychopharmacol 9:135\u2013145","journal-title":"Int J Neuropsychopharmacol"},{"key":"812_CR6","unstructured":"Buckley PF (2007) Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 68(suppl 6):5\u20139"},{"key":"812_CR7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.schres.2006.12.032","volume":"94","author":"PF Buckley","year":"2007","unstructured":"Buckley PF, Harvey PD, Bowie CR, Loebel A (2007) The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr Res 94:99\u2013106","journal-title":"Schizophr Res"},{"key":"812_CR8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/106002809502900210","volume":"29","author":"CF Caley","year":"1995","unstructured":"Caley CF, Weber SS (1995) Sulpride: an antipsychotic with selective dopaminergic antagonist properties. Ann Pharmacother 29:152\u2013160","journal-title":"Ann Pharmacother"},{"key":"812_CR9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/oxfordjournals.schbul.a033484","volume":"26","author":"JA Cramer","year":"2000","unstructured":"Cramer JA, Rosenheck R, Xu W, Thomas J, Henderson W, Charney DS (2000) Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on clozapine in refractory schizophrenia. Schizophr Bull 26:659\u2013666","journal-title":"Schizophr Bull"},{"key":"812_CR10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pnpbp.2003.10.010","volume":"28","author":"MR Dossenbach","year":"2004","unstructured":"Dossenbach MR, Folnegovic-Smalc V, Hotujac L, Uglesic B, Tollefson GD, Grundy SL, Friedel P, Jakovljevic MM (2004) Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:311\u2013318","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"812_CR11","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1176\/ajp.2006.163.12.2090","volume":"163","author":"SM Essock","year":"2006","unstructured":"Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA (2006) Effectiveness of switching antipsychotic medications. Am J Psychiatry 163:2090\u20132095","journal-title":"Am J Psychiatry"},{"key":"812_CR12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/15622970510030090","volume":"6","author":"P Falkai","year":"2005","unstructured":"Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ (2005) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6:132\u2013191","journal-title":"World J Biol Psychiatry"},{"key":"812_CR13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/15622970500483177","volume":"7","author":"P Falkai","year":"2006","unstructured":"Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Moller HJ (2006) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 7:5\u201340","journal-title":"World J Biol Psychiatry"},{"key":"812_CR14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1192\/bjp.170.5.422","volume":"170","author":"M Franz","year":"1997","unstructured":"Franz M, Lis S, Pluddemann K, Gallhofer B (1997) Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 170:422\u2013425","journal-title":"Br J Psychiatry"},{"key":"812_CR15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1017\/S1092852900026675","volume":"11","author":"ID Glick","year":"2006","unstructured":"Glick ID (2006) Understanding the results of CATIE in the context of the field. CNS Spectr 11:40\u201347","journal-title":"CNS Spectr"},{"key":"812_CR16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-0447.1995.tb09751.x","volume":"91","author":"U Hegerl","year":"1995","unstructured":"Hegerl U, Juckel G, Muller-Schubert A, Pietzcker A, Gaebel W (1995) Schizophrenics with small P300: a subgroup with a neurodevelopmental disturbance and a high risk for tardive dyskinesia? Acta Psychiatr Scand 91:120\u2013125","journal-title":"Acta Psychiatr Scand"},{"key":"812_CR17","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","volume":"10","author":"DW Heinrichs","year":"1984","unstructured":"Heinrichs DW, Hanlon TE, Carpenter WT Jr (1984) The Quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10:388\u2013398","journal-title":"Schizophr Bull"},{"key":"812_CR18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","volume":"163","author":"S Heres","year":"2006","unstructured":"Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S (2006) Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163:185\u2013194","journal-title":"Am J Psychiatry"},{"key":"812_CR19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/00004714-200012000-00019","volume":"20","author":"A Hofer","year":"2000","unstructured":"Hofer A, Hummer M, Huber R, Kurz M, Walch T, Fleischhacker WW (2000) Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol 20:699\u2013702","journal-title":"J Clin Psychopharmacol"},{"key":"812_CR20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/archpsyc.1973.01750310038007","volume":"28","author":"GE Hogarty","year":"1973","unstructured":"Hogarty GE, Goldberg SC (1973) Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates. Arch Gen Psychiatry 28:54\u201364","journal-title":"Arch Gen Psychiatry"},{"key":"812_CR21","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4088\/JCP.v67n0606","volume":"67","author":"GW Hugenholtz","year":"2006","unstructured":"Hugenholtz GW, Heerdink ER, Stolker JJ, Meijer WE, Egberts AC, Nolen WA (2006) Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry 67:897\u2013903","journal-title":"J Clin Psychiatry"},{"key":"812_CR22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","volume":"63","author":"PB Jones","year":"2006","unstructured":"Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079\u20131087","journal-title":"Arch Gen Psychiatry"},{"key":"812_CR23","doi-asserted-by":"crossref","first-page":"831","DOI":"10.4088\/JCP.v67n0519","volume":"67","author":"JM Kane","year":"2006","unstructured":"Kane JM (2006) Commentary on the clinical antipsychotic trials of intervention effectiveness (CATIE). J Clin Psychiatry 67:831\u2013832","journal-title":"J Clin Psychiatry"},{"key":"812_CR24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-002-1052-z","volume":"162","author":"A Karow","year":"2002","unstructured":"Karow A, Naber D (2002) Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl) 162:3\u201310","journal-title":"Psychopharmacology (Berl)"},{"key":"812_CR25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/15622970600685424","volume":"7","author":"S Kasper","year":"2006","unstructured":"Kasper S, Winkler D (2006) Addressing the limitations of the CATIE study. World J Biol Psychiatry 7:126\u2013127","journal-title":"World J Biol Psychiatry"},{"issue":"Suppl 1","key":"812_CR26","first-page":"S1","volume":"16","author":"DJ Kupfer","year":"2003","unstructured":"Kupfer DJ, Sartorius N (2003) The usefulness and use of second-generation antipsychotic medication\u2014an update. Curr Opin Psychiatry 16(suppl 1):S1\u2013S44","journal-title":"Curr Opin Psychiatry"},{"key":"812_CR27","doi-asserted-by":"crossref","unstructured":"Lambert M, Naber D (2004) Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 18(suppl 2):5\u201317","DOI":"10.2165\/00023210-200418002-00002"},{"key":"812_CR28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/j.1552-4604.1991.tb03775.x","volume":"31","author":"MR Lavin","year":"1991","unstructured":"Lavin MR, Rifkin A (1991) Prophylactic antiparkinson drug use: II. Withdrawal after long-term maintenance therapy. J Clin Pharmacol 31:769\u2013777","journal-title":"J Clin Pharmacol"},{"key":"812_CR29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/oxfordjournals.schbul.a007071","volume":"30","author":"AF Lehman","year":"2004","unstructured":"Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, Tenhula WN, Boerescu D, Tek C et al (2004) The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 30:193\u2013217","journal-title":"Schizophr Bull"},{"key":"812_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/appi.ajp.161.1.1","volume":"161","author":"AF Lehman","year":"2004","unstructured":"Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J (2004) Practice guideline for the treatment of patients with schizophrenia, 2nd edn. Am J Psychiatry 161:1\u201356","journal-title":"Am J Psychiatry"},{"key":"812_CR31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","volume":"35","author":"S Leucht","year":"1999","unstructured":"Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999) Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35:51\u201368","journal-title":"Schizophr Res"},{"key":"812_CR32","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","volume":"32","author":"SW Lewis","year":"2006","unstructured":"Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB (2006) Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 32:715\u2013723","journal-title":"Schizophr Bull"},{"key":"812_CR33","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archpsyc.63.10.1069","volume":"63","author":"JA Lieberman","year":"2006","unstructured":"Lieberman JA (2006) Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch Gen Psychiatry 63:1069\u20131072","journal-title":"Arch Gen Psychiatry"},{"key":"812_CR34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/npp.1994.40","volume":"11","author":"JA Lieberman","year":"1994","unstructured":"Lieberman JA, Alvir J, Geisler S, Ramos-Lorenzi J, Woerner M, Novacenko H, Cooper T, Kane JM (1994) Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. Neuropsychopharmacology 11:107\u2013118","journal-title":"Neuropsychopharmacology"},{"key":"812_CR35","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209\u20131223","journal-title":"N Engl J Med"},{"key":"812_CR36","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1176\/appi.ajp.160.8.1396","volume":"160","author":"JA Lieberman","year":"2003","unstructured":"Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R et al (2003) Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160:1396\u20131404","journal-title":"Am J Psychiatry"},{"key":"812_CR37","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1007\/s00115-007-2308-y","volume":"78","author":"W Maier","year":"2007","unstructured":"Maier W, Moller HJ (2007) Meta-analyses: a tool for maximizing therapy study evidence?. Nervenarzt 78:1028\u20131036","journal-title":"Nervenarzt"},{"key":"812_CR38","first-page":"114","volume":"47","author":"N Manos","year":"1986","unstructured":"Manos N, Lavrentiadis G, Gkiouzepas J (1986) Evaluation of the need for prophylactic antiparkinsonian medication in psychotic patients treated with neuroleptics. J Clin Psychiatry 47:114\u2013116","journal-title":"J Clin Psychiatry"},{"key":"812_CR39","doi-asserted-by":"crossref","unstructured":"McCue RE, Waheed R, Urcuyo L, Orendain G, Joseph MD, Charles R, Hasan SM (2006) Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 189: 433\u2013440","DOI":"10.1192\/bjp.bp.105.019307"},{"key":"812_CR40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","volume":"163","author":"JP McEvoy","year":"2006","unstructured":"McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE et al (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600\u2013610","journal-title":"Am J Psychiatry"},{"key":"812_CR41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1017\/S109285290002664X","volume":"11","author":"HY Meltzer","year":"2006","unstructured":"Meltzer HY, Bobo WV (2006) Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS Spectr 11:14\u201324","journal-title":"CNS Spectr"},{"key":"812_CR42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.schres.2005.07.034","volume":"80","author":"DD Miller","year":"2005","unstructured":"Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RS, Rosenheck RA, Stroup TS et al (2005) Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 80:33\u201343","journal-title":"Schizophr Res"},{"key":"812_CR43","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0924-9338(00)00229-7","volume":"15","author":"HJ M\u00f6ller","year":"2000","unstructured":"M\u00f6ller HJ (2000) Rating depressed patients: observer- vs self-assessment. Eur Psychiatry 15:160\u2013172","journal-title":"Eur Psychiatry"},{"key":"812_CR44","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.pnpbp.2003.09.006","volume":"27","author":"HJ M\u00f6ller","year":"2003","unstructured":"M\u00f6ller HJ (2003) Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1101\u20131111","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"812_CR45","first-page":"85","volume":"10","author":"HJ M\u00f6ller","year":"2003","unstructured":"M\u00f6ller HJ (2003) Plazebo-kontrollierte Studien zum Wirkungsnachweis von Antidepressiva sind notwendig! Psychopharmakotherapie 10:85\u201386","journal-title":"Psychopharmakotherapie"},{"key":"812_CR46","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00115-004-1690-y","volume":"5","author":"HJ M\u00f6ller","year":"2004","unstructured":"M\u00f6ller HJ (2004) Sind placebokontrollierte Studien zum Wirksamkeitsbeweis von Antidepressiva notwendig? Nervenarzt 5:421\u2013424","journal-title":"Nervenarzt"},{"key":"812_CR47","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00406-005-0634-2","volume":"255","author":"HJ M\u00f6ller","year":"2005","unstructured":"M\u00f6ller HJ (2005) Are the new antipsychotics no better than the classical neuroleptics? The problematic answer from the CATIE study. Eur Arch Psychiatry Clin Neurosci 255:371\u2013372","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"812_CR48","first-page":"45","volume":"14","author":"HJ M\u00f6ller","year":"2007","unstructured":"M\u00f6ller HJ (2007) \u201cEffectiveness\u201d-Studien: methodische M\u00e4ngel und negative Konsequenzen f\u00fcr die Versorgung. Psychopharmakotherapie 14:45\u201346","journal-title":"Psychopharmakotherapie"},{"key":"812_CR49","doi-asserted-by":"crossref","unstructured":"M\u00f6ller HJ (2008) Standardised rating scales in psychiatry: methodological basis, possibilities, limitations and descriptions of important rating scales. World J Biol Psychiatry (in press)","DOI":"10.1080\/15622970802264606"},{"key":"812_CR50","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00115-007-2291-3","volume":"78","author":"HJ Moller","year":"2008","unstructured":"Moller HJ, Maier W (2007) Problems of evidence-based medicine in psychopharmacotherapy: problems of evidence grading and of the evidence basis for complex clinical decision making. Nervenarzt 78:1014\u20131027","journal-title":"Nervenarzt"},{"key":"812_CR51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13651500510014783","volume":"9","author":"MAC Mudge","year":"2005","unstructured":"Mudge MAC, Davey PJ, Coleman KA, Montgomery W, Croker VS, Mullen K, Castle DJ (2005) A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials. Int J Psychiatry Clin Prac 9:3\u201315","journal-title":"Int J Psychiatry Clin Prac"},{"key":"812_CR52","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/sj.npp.1300984","volume":"31","author":"C Mulert","year":"2006","unstructured":"Mulert C, Juckel G, Giegling I, Pogarell O, Leicht G, Karch S, Mavrogiorgou P, Moller HJ, Hegerl U, Rujescu D (2006) A Ser9Gly polymorphism in the dopamine D3 receptor gene (DRD3) and event-related P300 potentials. Neuropsychopharmacology 31:1335\u20131344","journal-title":"Neuropsychopharmacology"},{"key":"812_CR53","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/schbul\/18.2.319","volume":"18","author":"RM Murray","year":"1992","unstructured":"Murray RM, O\u2019Callaghan E, Castle DJ, Lewis SW (1992) A neurodevelopmental approach to the classification of schizophrenia. Schizophr Bull 18:319\u2013332","journal-title":"Schizophr Bull"},{"key":"812_CR54","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1097\/00004714-199804001-00002","volume":"18","author":"RM Murray","year":"1998","unstructured":"Murray RM, Van Os J (1998) Predictors of outcome in schizophrenia. J Clin Psychopharmacol 18:2S\u20134S","journal-title":"J Clin Psychopharmacol"},{"key":"812_CR55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1600-0447.2004.00478.x","volume":"111","author":"D Naber","year":"2005","unstructured":"Naber D (2005) Subjective effects of antipsychotic treatment. Acta Psychiatr Scand 111:81\u201383","journal-title":"Acta Psychiatr Scand"},{"key":"812_CR56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S1461145704004262","volume":"7","author":"P Oosthuizen","year":"2004","unstructured":"Oosthuizen P, Emsley R, Jadri TH, Keyter N (2004) A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. Int J Neuropsychopharmacol 7:125\u2013131","journal-title":"Int J Neuropsychopharmacol"},{"key":"812_CR57","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4088\/JCP.v64n0913","volume":"64","author":"PP Oosthuizen","year":"2003","unstructured":"Oosthuizen PP, Emsley RA, Maritz JS, Turner JA, Keyter N (2003) Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 64:1075\u20131080","journal-title":"J Clin Psychiatry"},{"key":"812_CR58","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/978-3-642-70486-4_30","volume-title":"Assessment of depression","author":"ES Paykel","year":"1986","unstructured":"Paykel ES, Norton KRW (1986) Self-report and clinical interview in the assessment of depression. In: Sartorius N, Ban TA (eds) Assessment of depression. Springer, New York, pp 356\u2013366"},{"key":"812_CR59","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4088\/JCP.v67n0910","volume":"67","author":"GA Phillips","year":"2006","unstructured":"Phillips GA, Van Brunt DL, Roychowdhury SM, Xu W, Naber D (2006) The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. J Clin Psychiatry 67:1397\u20131403","journal-title":"J Clin Psychiatry"},{"key":"812_CR60","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s004060070028","volume":"250","author":"R Pukrop","year":"2000","unstructured":"Pukrop R, M\u00f6ller HJ, Steinmeyer EM (2000) Quality of life in psychiatry: a systematic contribution to construct validation and the development of the integrative assessment tool \u201cmodular system for quality of life\u201d. Eur Arch Psychiatry Clin Neurosci 250:120\u2013132","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"812_CR61","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0165-1781(03)00110-0","volume":"119","author":"R Pukrop","year":"2003","unstructured":"Pukrop R, Schlaak V, M\u00f6ller-Leimk\u00fchler AM, Albus M, Czernik A, Klosterk\u00f6tter J, M\u00f6ller HJ (2003) Reliability and validity of quality of life assessed by the Short-Form 36 and the modular system of quality of life in patients with schizophrenia and patients with depression. Psych Res 119:63\u201379","journal-title":"Psych Res"},{"key":"812_CR62","first-page":"208","volume":"41","author":"JM Pyne","year":"2003","unstructured":"Pyne JM, Sullivan G, Kaplan R, Williams DK (2003) Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia. Med Care 41:208\u2013217","journal-title":"Med Care"},{"key":"812_CR63","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1176\/appi.ps.56.12.1489","volume":"56","author":"M Ragins","year":"2005","unstructured":"Ragins M (2005) Should the CATIE study be a wake-up call? Psychiatr Serv 56:1489","journal-title":"Psychiatr Serv"},{"key":"812_CR64","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","volume":"290","author":"R Rosenheck","year":"2003","unstructured":"Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S et al (2003) Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290:2693\u20132702","journal-title":"JAMA"},{"key":"812_CR65","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/archpsyc.63.10.1074","volume":"63","author":"RA Rosenheck","year":"2006","unstructured":"Rosenheck RA (2006) Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1074\u20131076","journal-title":"Arch Gen Psychiatry"},{"key":"812_CR66","volume-title":"The American psychiatric publishing textbook of psychopharmacology","author":"AF Schatzberg","year":"2000","unstructured":"Schatzberg AF, Nemeroff CB (2000) The American psychiatric publishing textbook of psychopharmacology, 3rd edn. American Psychiatric Publishing, Washington DC","edition":"3"},{"key":"812_CR67","unstructured":"Soares BG, Fenton M, Chue P (2000) Sulpiride for schizophrenia. Cochrane Database Syst Rev: CD001162"},{"key":"812_CR68","unstructured":"Soares KV, McGrath JJ (2000) Anticholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev: CD000204"},{"key":"812_CR69","first-page":"305","volume":"47","author":"JJ Sramek","year":"1986","unstructured":"Sramek JJ, Simpson GM, Morrison RL, Heiser JF (1986) Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study. J Clin Psychiatry 47:305\u2013309","journal-title":"J Clin Psychiatry"},{"key":"812_CR70","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF00432269","volume":"61","author":"TA Stern","year":"1979","unstructured":"Stern TA, Anderson WH (1979) Benztropine prophylaxis of dystonic reactions. Psychopharmacology (Berl) 61:261\u2013262","journal-title":"Psychopharmacology (Berl)"},{"key":"812_CR71","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","volume":"163","author":"TS Stroup","year":"2006","unstructured":"Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J et al (2006) Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163:611\u2013622","journal-title":"Am J Psychiatry"},{"key":"812_CR72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/oxfordjournals.schbul.a006986","volume":"29","author":"TS Stroup","year":"2003","unstructured":"Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA (2003) The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 29:15\u201331","journal-title":"Schizophr Bull"},{"key":"812_CR73","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/hup.764","volume":"21","author":"RD Strous","year":"2006","unstructured":"Strous RD, Kupchik M, Roitman S, Schwartz S, Gonen N, Mester R, Weizman A, Spivak B (2006) Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. Hum Psychopharmacol 21:235\u2013243","journal-title":"Hum Psychopharmacol"},{"key":"812_CR74","doi-asserted-by":"crossref","unstructured":"Tandon R, M\u00f6ller HJ, Belmaker RH, Gattaz WF, Lopez-Ibor JJ, Okasha A, Burrows G, Stein DJ, Olie JP, Nutt D, et al. (2008) World Psychiatric Association Pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res (in press)","DOI":"10.1016\/j.schres.2007.11.033"},{"key":"812_CR75","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.38881.382755.2F","volume":"333","author":"J Tiihonen","year":"2006","unstructured":"Tiihonen J, Walhbeck K, Lonnqvist J, Klaukka T, Ioannidis JP, Volavka J, Haukka J (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 333:224","journal-title":"BMJ"},{"key":"812_CR76","unstructured":"Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK (1999) Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J Clin Psychiatry 60 (suppl 19):38\u201345"},{"key":"812_CR77","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.290.12.1624","volume":"290","author":"SR Tunis","year":"2003","unstructured":"Tunis SR, Stryer DB, Clancy CM (2003) Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 290:1624\u20131632","journal-title":"JAMA"},{"key":"812_CR78","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE, Jr., Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473\u2013483","journal-title":"Med Care"},{"key":"812_CR79","volume-title":"SF-36 Health Survey Manual and Interpretation Guide","author":"JE Ware","year":"1993","unstructured":"Ware JE, Snow KK, Kosinski M, Gandek B (1993) SF-36 Health Survey Manual and Interpretation Guide. The Health Institute, New England Medical Center, Boston"},{"key":"812_CR80","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0269881105056668","volume":"20","author":"PJ Weiden","year":"2006","unstructured":"Weiden PJ (2006) Switching antipsychotics: an updated review with a focus on quetiapine. J Psychopharmacol 20:104\u2013118","journal-title":"J Psychopharmacol"},{"key":"812_CR81","unstructured":"Weiden PJ (2007) Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry 68(suppl 1):12\u20139"},{"key":"812_CR82","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4088\/JCP.v64n0514","volume":"64","author":"PJ Weiden","year":"2003","unstructured":"Weiden PJ, Simpson GM, Potkin SG, O\u2019Sullivan RL (2003) Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 64:580\u2013588","journal-title":"J Clin Psychiatry"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-008-0812-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-008-0812-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-008-0812-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T14:20:08Z","timestamp":1559053208000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-008-0812-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,11]]},"references-count":82,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["812"],"URL":"https:\/\/doi.org\/10.1007\/s00406-008-0812-0","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,11]]}}}